Idiopathic pulmonary fibrosis (IPF)
Although the cause of IPF is not clear, smoking, viral infections and previous family history of the condition are contributing factors. Patients with IPF often have chronic exertional dyspnoea, bibasilar lung crackles (‘Velcro’ crackles) and finger clubbing. Physicians should consider IPF in patients with these signs and a definitive diagnosis can be made based on characteristic imaging and histological patterns.
Treating IPF includes pharmacological and pulmonary rehabilitation approaches. Effective disease-modifying treatments are available which is why it is important to diagnose and treat IPF as early as possible. In extreme cases of IPF a lung transplant may be needed.
To find out how to recognise and treat idiopathic pulmonary fibrosis, visit our dedicated Learning Zone which contains further information and expert opinion on diagnosis and current IPF treatment guidelines.
Featured Learning Zones
Find out more about IPF in the disease awareness section, such as epidemiology, pathophysiology, symptoms and diagnosis. Learn about the latest interventions available for patients in the treatment section, including treatment pathways and guideline recommendations.
Related news and insights
Boehringer Ingelheim announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).